肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

静脉注射用免疫球蛋白在儿童血液/肿瘤性疾病中应用的儿科专家共识

2021-04-10 中国当代儿科杂志.2021,23(4):319-327.

免疫球蛋白

静脉注射用免疫球蛋白（IVIG）在恶性血液肿瘤化疗、靶向治疗及造血干细胞移植中的应用越来越普遍，但国内外尚无儿童血液/ 肿瘤性疾病中IVIG 应用的临床指南或共识。该共识基于儿童血液/ 肿瘤性疾病中I

中文标题：

静脉注射用免疫球蛋白在儿童血液/肿瘤性疾病中应用的儿科专家共识

发布机构：

发布日期：

2021-04-10

简要介绍：

静脉注射用免疫球蛋白（IVIG）在恶性血液肿瘤化疗、靶向治疗及造血干细胞移植中的应用越来越普遍，但国内外尚无儿童血液/ 肿瘤性疾病中IVIG 应用的临床指南或共识。该共识基于儿童血液/ 肿瘤性疾病中IVIG 应用的国内外研究进展而制定，对IVIG 在儿童血液/ 肿瘤性疾病中的临床应用策略及其不良反应的防治提出具体建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=静脉注射用免疫球蛋白在儿童血液.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9e43e1c00208e596, title=静脉注射用免疫球蛋白在儿童血液/肿瘤性疾病中应用的儿科专家共识, enTitle=, guiderFrom=中国当代儿科杂志.2021,23(4):319-327., authorId=0, author=, summary=静脉注射用免疫球蛋白（IVIG）在恶性血液肿瘤化疗、靶向治疗及造血干细胞移植中的应用越来越普遍，但国内外尚无儿童血液/ 肿瘤性疾病中IVIG 应用的临床指南或共识。该共识基于儿童血液/ 肿瘤性疾病中I, cover=https://img.medsci.cn/2021424/1619278690541_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Sat Apr 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>静脉注射用免疫球蛋白（IVIG）在恶性血液肿瘤化疗、靶向治疗及造血干细胞移植中的应用越来越普遍，但国内外尚无儿童血液/ 肿瘤性疾病中IVIG 应用的临床指南或共识。该共识基于儿童血液/ 肿瘤性疾病中IVIG 应用的国内外研究进展而制定，对IVIG 在儿童血液/ 肿瘤性疾病中的临床应用策略及其不良反应的防治提出具体建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=4108, tagName=免疫球蛋白)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4108, guiderKeyword=免疫球蛋白, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3829, appHits=93, showAppHits=0, pcHits=247, showPcHits=3735, likes=3, shares=8, comments=8, approvalStatus=1, publishedTime=Sat Apr 24 23:41:20 CST 2021, publishedTimeString=2021-04-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Apr 24 23:38:18 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:52:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=静脉注射用免疫球蛋白在儿童血液.pdf)])
静脉注射用免疫球蛋白在儿童血液.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1235361, encodeId=24841235361eb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc55266753, createdName=不知怎么, createdTime=Thu Jul 28 20:57:30 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074586, encodeId=844d10e4586e9, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 19:52:05 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062323, encodeId=d53510623233d, content=学习一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3c5555302, createdName=ms2000001082758263, createdTime=Wed Oct 20 18:32:57 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013244, encodeId=5782101324489, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56812497153, createdName=张家小胖子爱学习, createdTime=Tue Aug 31 17:21:18 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971208, encodeId=4ac19e1208f2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Jun 05 23:10:59 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2022-07-28 不知怎么

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1235361, encodeId=24841235361eb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc55266753, createdName=不知怎么, createdTime=Thu Jul 28 20:57:30 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074586, encodeId=844d10e4586e9, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 19:52:05 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062323, encodeId=d53510623233d, content=学习一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3c5555302, createdName=ms2000001082758263, createdTime=Wed Oct 20 18:32:57 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013244, encodeId=5782101324489, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56812497153, createdName=张家小胖子爱学习, createdTime=Tue Aug 31 17:21:18 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971208, encodeId=4ac19e1208f2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Jun 05 23:10:59 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-11-27 ms8000001755238620

    学习下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1235361, encodeId=24841235361eb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc55266753, createdName=不知怎么, createdTime=Thu Jul 28 20:57:30 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074586, encodeId=844d10e4586e9, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 19:52:05 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062323, encodeId=d53510623233d, content=学习一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3c5555302, createdName=ms2000001082758263, createdTime=Wed Oct 20 18:32:57 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013244, encodeId=5782101324489, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56812497153, createdName=张家小胖子爱学习, createdTime=Tue Aug 31 17:21:18 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971208, encodeId=4ac19e1208f2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Jun 05 23:10:59 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-10-20 ms2000001082758263

    学习一下。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1235361, encodeId=24841235361eb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc55266753, createdName=不知怎么, createdTime=Thu Jul 28 20:57:30 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074586, encodeId=844d10e4586e9, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 19:52:05 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062323, encodeId=d53510623233d, content=学习一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3c5555302, createdName=ms2000001082758263, createdTime=Wed Oct 20 18:32:57 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013244, encodeId=5782101324489, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56812497153, createdName=张家小胖子爱学习, createdTime=Tue Aug 31 17:21:18 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971208, encodeId=4ac19e1208f2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Jun 05 23:10:59 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-08-31 张家小胖子爱学习

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1235361, encodeId=24841235361eb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc55266753, createdName=不知怎么, createdTime=Thu Jul 28 20:57:30 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074586, encodeId=844d10e4586e9, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 19:52:05 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062323, encodeId=d53510623233d, content=学习一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3c5555302, createdName=ms2000001082758263, createdTime=Wed Oct 20 18:32:57 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013244, encodeId=5782101324489, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56812497153, createdName=张家小胖子爱学习, createdTime=Tue Aug 31 17:21:18 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971208, encodeId=4ac19e1208f2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Jun 05 23:10:59 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-06-05 120c570cm03暂无昵称

    谢谢

    0

拓展阅读

人特异性免疫球蛋白药学研究与评价技术指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2021-10-13

2022 BSI/UKPIN共识指南：免疫球蛋白替代治疗管理

英国免疫学会(BSI,British Society for Immunology) · 2022-10-21

分子定义的亚洲型 DEL 女性 Rho(D) 免疫球蛋白指南 (c.1227G>A)

韩国检验医学学会(KSLM,Korean Society for Laboratory Medicine) · 2024-02-22

静脉注射用免疫球蛋白在血液系统疾病中应用的专家共识

暂未更新 · 2024-03-20